JLE

Hépato-Gastro & Oncologie Digestive

MENU

Comment optimiser la surveillance des lésions gastriques pré-néoplasiques ? Volume 26, numéro 7, Septembre 2019

  • [1] Bray F., Ferlay J., Soerjomataram I. Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.
  • [2] Song Z., Wu Y., Yang J., Yang D., Fang X. Progress in the treatment of advanced gastric cancer. Tumour Biol. 2017;39:1010428317714626. 7
  • [3] Mackenzie M., Spithoff K., Jonker D. Systemic therapy for advanced gastric cancer: A clinical practice guideline. Curr Oncol. 201118-202.
  • [4] Defossez G, Le Guyader-Peyrou S, Uhry Z, et al. Estimations nationales de l’incidence et de la mortalité par cancer en France métropolitaine entre 1990 et 2018. Étude à partir des registres des cancers du réseau Francim. Résultats préliminaires. Paris : Santé publique France. Disponible à l’adresse suivante : http://invs.santepubliquefrance.fr/Publications-et-outils/Rapports-et-syntheses/Maladies-chroniques-et-traumatismes/2019/Estimations-nationales-de-l-incidence-et-de-la-mortalite-par-cancer-en-France-metropolitaine-entre-1990-et-2018.
  • [5] Song H., Held M., Sandin S. Increase in the Prevalence of Atrophic Gastritis Among Adults Age 35 to 44 Years Old in Northern Sweden Between 1990 and 2009. Clin Gastroenterol Hepatol. 2015;13:1592-1600.
  • [6] Hamashima C. Systematic Review Group and Guideline Development Group for Gastric Cancer Screening Guidelines. Update version of the Japanese Guidelines for Gastric Cancer Screening. Jpn J Clin Oncol. 2018;48:673-683.
  • [7] Belot A, Velten M, Grosclaude P, et al. Estimation nationale de l’incidence et de la mortalité par cancer en France entre 1980 et 2005. Publications de l’Institut de Veille Sanitaire, 2009.
  • [8] Fukao A., Hisamichi S., Ohsato N. Correlation between the prevalence of gastritis and gastric cancer in Japan. Cancer Causes Control. 1993;4:17-20.
  • [9] Genta R.M. Review article : Gastric atrophy and atrophic gastritis--nebulous concepts in search of a definition. Aliment Pharmacol Ther. 1998;12:17-23. Suppl. 1
  • [10] Kapadia C.R. Gastric atrophy, metaplasia, and dysplasia: A clinical perspective. J Clin Gastroenterol. 2003;36:S29-36. discussion S61-62
  • [11] Con S.A., Con-Wong R., Con-Chin G.R. Serum pepsinogen levels, Helicobacter pylori CagA Status, and cytokine gene polymorphisms associated with gastric premalignant lesions in Costa Rica. Cancer Epidemiol Biomark Prev. 2007;16:2631-2636.
  • [12] Lauren P. The Two Histological Main Types of Gastric Carcinoma : Diffuse and So-Called Intestinal-Type Carcinoma. An Attempt at a Histo-Clinical Classification. Acta Pathol Microbiol Scand. 1965;64:31-49.
  • [13] El-Omar E.M., Oien K., El-Nujumi A. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology. 1997;113:15-24.
  • [14] Suerbaum S., Michetti P. Helicobacter pylori infection. N Engl J Med. 2002;347:1175-1186.
  • [15] de Vries AC, van Grieken NC, Looman CW, et al. Gastric cancer risk in patients with premalignant gastric lesions : A nationwide cohort study in the Netherlands. Gastroenterology 2008 ; 134 : 945-52.
  • [16] Leung W.K., Ng E.K., Chan W.Y. Risk factors associated with the development of intestinal metaplasia in first-degree relatives of gastric cancer patients. Cancer Epidemiol Biomarkers Prev. 2005;14:2982-2986. 12
  • [17] Rokkas T., Sechopoulos P., Pistiolas D. Helicobacter pylori infection and gastric histology in first-degree relatives of gastric cancer patients: A meta-analysis. Eur J Gastroenterol Hepatol. 2010;22:1128-1133.
  • [18] Kato I., Vivas J., Plummer M. Environmental factors in Helicobacter pylori-related gastric precancerous lesions in Venezuela. Cancer Epidemiol Biomark Prev. 2004;13:468-476.
  • [19] Schenk B.E., Kuipers E.J., Nelis G.F. Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy. Gut. 2000;46:615-621.
  • [20] Kuipers E.J., Nelis G.F., Klinkenberg-Knol E.C. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease : results of a randomised controlled trial. Gut. 2004;53:12-20.
  • [21] Waddingham W, Graham D, Banks, et al. The evolving role of endoscopy in the diagnosis of premalignant gastric lesions. F1000Research 2018 ; 7.
  • [22] Correa P. Human gastric carcinogenesis: A multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992;52:6735-6740.
  • [23] Murphy G., Pfeiffer R., Camargo M.C. Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology. 2009;137:824-833.
  • [24] van der Post R.S., Gullo I., Oliveira C. Histopathological, molecular, and genetic profile of hereditary diffuse gastric cancer: Current knowledge and challenges for the future. Adv Exp Med Biol. 2016;908:371-391.
  • [25] Gutierrez-Gonzalez L, Graham TA, Rodriguez-Justo M, et al. The clonal origins of dysplasia from intestinal metaplasia in the human stomach. Gastroenterology 2011 ; 140 : 1251-1260.
  • [26] Lavery D.L., Martinez P., Gay L.J. Evolution of oesophageal adenocarcinoma from metaplastic columnar epithelium without goblet cells in Barrett's oesophagus. Gut. 2016;65:907-913.
  • [27] El-Zimaity H.M., Graham D.Y. Evaluation of gastric mucosal biopsy site and number for identification of Helicobacter pylori or intestinal metaplasia: Role of the Sydney . Hum Pathol. 1999;30:72-77. System
  • [28] de Vries A.C., Haringsma J., de Vries R.A. Biopsy strategies for endoscopic surveillance of pre-malignant gastric lesions. Helicobacter. 2010;15:259-264.
  • [29] Atkins L., Benedict E.B. Correlation of gross gastroscopic findings with gastroscopic biopsy in gastritis. N Engl J Med. 1956;254:641-644.
  • [30] Stathopoulos G., Goldberg R.D., Blackstone M.O. Endoscopic diagnosis of intestinal metaplasia. Gastrointest Endosc. 1990;36:544-545.
  • [31] Redéen S., Petersson F., Jönsson K.A., Borch K. Relationship of gastroscopic features to histological findings in gastritis and Helicobacter pylori infection in a general population sample. Endoscopy. 2003;35:946-950. 11
  • [32] Dixon M.F., Genta R.M., Yardley J.H. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996;20:1161-1181.
  • [33] Rugge M, de Boni M, Pennelli G, et al. Gastritis OLGA-staging and gastric cancer risk: A twelve-year clinico-pathological follow-up study. Aliment Pharmacol Ther 2010 ; 31 : 1104-11.
  • [34] Satoh K., Kimura K., Taniguchi Y. Biopsy sites suitable for the diagnosis of Helicobacter pylori infection and the assessment of the extent of atrophic gastritis. Am J Gastroenterol. 1998;93:569-573.
  • [35] Eriksson NK1, Färkkilä M.A., Voutilainen M.E., Arkkila P.E. The clinical value of taking routine biopsies from the incisura angularis during gastroscopy. Endoscopy. 2005;37:532-536. 6
  • [36] Van Zanten S.J., Dixon M.F., Lee A. The gastric transitional zones: Neglected links between gastroduodenal pathology and helicobacter ecology. Gastroenterology. 1999;116:1217-1229.
  • [37] Cassaro M., Rugge M., Gutierrez O. Topographic patterns of intestinal metaplasia and gastric cancer. Am J Gastroenterol. 2000;95:1431-1438.
  • [38] Rugge M., Meggio A., Pennelli G. Gastritis staging in clinical practice: The OLGA staging system. Gut. 2007;56:631-636.
  • [39] Capelle L.G., de Vries A.C., Haringsma J. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc. 2010;71:1150-1158.
  • [40] Dinis-Ribeiro M., Areia M., de Vries A.C. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy. 2012;44:74-94.
  • [41] Dinis-Ribeiro M., Kuipers E.J. Identification of gastric atrophic changes: From histopathology to endoscopy. Endoscopy. 2015;47:533-537.
  • [42] Kikuste I., Marques-Pereira R., Monteiro-Soares M. Systematic review of the diagnosis of gastric premalignant conditions and neoplasia with high-resolution endoscopic technologies. Scand J Gastroenterol. 2013;48:1108-1117.
  • [43] Jang J.S., Choi S.R., Qureshi W. Long-term outcomes of endoscopic submucosal dissection in gastric neoplastic lesions at a single institution in South Korea. Scand J Gastroenterol. 2009;44:1315-1322.
  • [44] de Vries AC, Meijer GA, Looman CWN, et al. Epidemiological trends of pre-malignant gastric lesions : a long-term nationwide study in the Netherlands. Gut 2007 ; 56 : 1665-70.
  • [45] Vannella L., Lahner E., Osborn J. Risk factors for progression to gastric neoplastic lesions in patients with atrophic gastritis. Aliment Pharmacol Ther. 2010;31:1042-1050.
  • [46] Pimentel-Nunes P, Libânio D, Marcos-Pinto R, et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy 2019 ; 51 : 365-88.